Inside the Academic Approach: How Initial Consultations for Bispecific Therapy Referrals Are Handled
Panelists discuss how academic centers approach the initial consultation and evaluation process for patients referred for bispecific therapy from community practices.
EP: 1.The Power of Partnership: Enhancing Patient Care in Multiple Myeloma through Academic and Community Physician Collaboration
EP: 2.Fast-Tracking Care: Streamlining Referrals for Quicker Treatment in Multiple Myeloma
EP: 3.Collaborative Care vs. Independent Treatment: Does It Impact Patient Outcomes in Multiple Myeloma?
EP: 4.Overcoming Challenges in Patient Referrals: Handling Reluctance and Navigating Barriers to Academic Care
EP: 5.When Is the Right Time? Navigating Key Moments for Referring Multiple Myeloma Patients to an Academic Center
EP: 6.Identifying and Referring Candidates for Bispecific Therapy: Key Factors in Transitioning from Community to Academic Care
EP: 7.Navigating the Challenges: Transitioning Patients from Community to Academic Settings in Multiple Myeloma Care
EP: 8.Inside the Academic Approach: How Initial Consultations for Bispecific Therapy Referrals Are Handled
EP: 9.Comparing Dosing and Management of BCMA vs Non-BCMA Bispecific Antibodies
EP: 10.Management of Bispecifc AE’s in the Community Setting of Multiple Myeloma Patients
EP: 11.Criteria for Transitioning Patients from Bispecific Therapy to Community Oncologist Care in Multiple Myeloma
EP: 12.Protocols for Monitoring and Managing Long-Term Complications of Bispecific Therapy in Mutlplie Myeloma
EP: 13.Enhancing Communication Between Academic and Community Oncologists During Referral and Treatment in Multiple Myeloma.
EP: 14.Optimizing Patient Reintegration into Community Care Post-Academic Treatment of Bispecifics in Multiple Myeloma
EP: 15.Unmet Needs and Future Directions for Enhancing Bispecific Therapy Care Transitions in Multiple Myeloma
Video content above is prompted by the following:
- From the academic center's perspective, how do you approach the initial consultation and evaluation process for patients referred for bispecific therapy from community practices?
![“[This approval] will be a quite dramatic change in our philosophy and practice in multiple myeloma," according to Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F3cab3ada4c023b68c118240a512e31d72a7f931b-1200x628.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“[This approval] will be a quite dramatic change in our philosophy and practice in multiple myeloma,\" according to Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
